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Abstract. Suitability of anti-erythrocyte F(ab')2-bearing liposomes as vehicles for 
chloroquine in the treatment of chloroquine resistant Plasmodium berghei infections in 
mice has been examined. Free chloroquine or chloroquine encapsulated in antibody-free 
liposomes failed to show much effect on the resistant infections, but the same doses of this 
drug after being encapsulated in antibody-bearing liposomes exhibited a significant 
inhibitory effect on this infection. These results indicate that chloroquine delivery in 
antibody targeted liposomes may help in the successful treatment of the chloroquine 
resistant malarial infections. 
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1. Introduction
 
Antibody-bearing liposomes are useful as carriers in drug targeting to specific cells 
in experimental animals (Agrawal et al 1987; Bankert et al 1989; Hospenthal et 
al 1989; Hughes et al 1989). We have previously shown (Singhal and Gupta 1986) 
that liposome binding to erythrocytes can be markedly increased by covalently 
attaching anti-erythrocyte F(ab')2 to the liposome surface. Also, it has been 
demonstrated that these liposomes could serve a useful purpose in drug homing to 
erythrocytes during malarial infections (Agrawal et al 1987). To further evaluate the 
usefulness of these liposomes as drug homing devices in malaria, we have now 
studied the efficacy of the liposomized chloroquine (chq) against both chq-sensitive 
and chq-resistant Plasmodium berghei infections in mice.
 
 
2. Materials and methods 
 
2.1 Materials 
 
Egg phosphatidylcholine (PC), egg [14C] PC and gangliosides were prepared as 
described earlier (Singhal et al 1986). Chloroquine diphosphate, sodium 
cyanoborohydride and pepsin were purchased from the Sigma Chemical Company 
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St. Louis, Mo, USA. Na [125I] (carrier-free) was obtained from the Bhabha Atomic 
Research Centre, Bombay. 
 
2.2 Liposomes 
 
Liposomes were prepared from egg PC (20 μmol), cholesterol (20 μmοl) and 
gangliosides (4 μmοl) in 0·8 ml of borate-buffered saline (10 mM borate, 60 Mm 
NaCl, pH 8·4) containing chloroquine diphosphate (350 μmοl) by sonication 
(Kumar and Gupta 1985) and fractionated by centrifugation (Kumar and Gupta 
1983). Free chq from drug entrapped liposomes was removed by gel filtration over 
Sephadex G-50 (Gupta and Bali 1981). The mean outer diameter of these liposomes, 
as determined by molecular sieve chromatography (Kumar and Gupta 1985) was 
about 45 nm. The amount of chq entrapped in liposomes was about 170 ± 3 μg/μ 
mol lipid P. 
 
2.3 Chq estimation 
 
Chq was estimated by measuring its absorbance at 342 nm as described earlier 
(Agrawal et al 1987). 
 
2.4 Anti-mouse erythrocyte F(ab')2 bearing liposomes
 
Anti-mouse erythrocyte antibodies were raised in rabbits and isolated from anti- 
serum following the procedure of Singhal et al (1986). The F(ab')2 fragments from 
the antibody were prepared, purified and covalently attached to the liposome 
surface as described earlier (Singhal et al 1986). The liposomes were passed through 
a millipore filter (pore size, 0·22 μm) prior to their use in animal experiments. The 
protein-to-lipid ratio (Singhal et al 1986) in the liposomes was about 90 μg 
protein/μmol lipid P. 
 
2.5 Animals 
 
Randomly bred Swiss mice were obtained from the animal house of our institute. 
Male mice (8–10 weeks old) of 20 ± 2 g weight were used. The animals were kept in 
plastic cages and given a diet of pellets (Hindustan Lever Limited) and water ad 
libitum. 
 
2.6 Parasites 
 
P. berghei parasites were obtained from the National Institute of Communicable
Diseases, New Delhi, and maintained in the Swiss mice through serial blood
passage. The strain was fully sensitive to chq; the ED 90 being 15 mg/kg × 4 days 
(i.p.). Parasitaemia was determined by counting 103 red cells in thin blood smear 
stained with Giemsa, and expressed as number of parasitized cells/100 erythrocytes.
 
2.7 Development of chq-resistance 
 
Chq-resistance was developed by the relapse technique, as described earlier 
(Warhurst and Folwell 1968). Mice were infected with about 107 P, berghei-infected 
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erythrocytes and on the same day, a single dose (60mg/kg, i.p.) of chq was 
administered. After the animals developed about 2% parasitaemia, the infected 
blood from these animals was transfused into healthy animals which were also 
given chq (60 mg/kg, i.p.) simultaneously. The above operation was repeated several 
times till the infection was rendered resistant to chq (50 mg/kg× 4 days, i.p.).
The chq-resistant P. berghei strain used in this study was developed about 4 years 
ago by us using the above technique, and has since been regularly maintained in 
mice under constant drug pressure. The strain retained its chq-resistant character 
for about a year even after withdrawing the drug pressure.
 
2.8 Drug treatment 
 
Swiss mice (4–5 animals/group) were infected on day zero with about 106 
erythrocytes infected with chq-sensitive or chq-resistant P. berghei strains. These 
animals were given a single intravenous dose of chq, chq loaded in non-targeted 
liposomes (free of F(ab')2) or chq encapsulated in targeted liposomes (bearing F(ab')2) 
on day 4 after the infection when parasitaemia was 0·01–0·10%. Parasitaemia was 
determined regularly from day 5. The per cent suppression of parasitaemia in 
animals treated with drug-laden liposomes was calculated by comparing the 
parasitaemias in these animals with those treated with an identical dose of free chq 
or buffer. 
 
3. Results 
 
Liposomes were formed from PC, cholesterol and gangliosides both in the presence 
and absence of chq by sonication and fractionated by ultracentrifugation. Most of 
the chq (over 90%) loaded in liposomes were found to reside in the liposomes 
internal aqueous phase rather than the lipid bilayer. Targeted liposomes were 
prepared by covalently attaching anti-mouse erythrocyte F(ab')2 to the non-targeted 
liposomes surface. Mice infected with chq-sensitive or chq-resistant P. berghei 
strains were given only one dose of free or liposomized chq by intravenous route on 
day 4 after the infection. This administration of liposomes did not induce hemolysis, 
as judged by the measurement of haemoglobin levels in plasma of the injected 
animals (data not shown). 
Erythrocyte surface structure and properties are altered during malarial infection 
(Howard 1982). It may thus be argued that the targeted liposome preparation used 
in this study could have an altered erythrocyte binding in infected mice as 
compared to the normal animals. To examine this possibility, we have determined 
the tissue distributions of liposomes before and after infecting the animals with P. 
berghei. Figure 1 shows that this distribution was not much affected by the 
infection, suggesting that the erythrocyte binding capacity of targeted liposomes 
was not influenced by infecting the animals with P. berghei (0·01–0·10% 
parasitaemia). 
Efficacy of chq against malarial infections was examined at its various doses in 
mice infected with chq-sensitive P. berghei. Free and liposomized chq were 
administered to the separate groups of infected animals, and the efficacy of this 
treatment was determined by comparing parasitaemias in these animals with those 
treated with saline. Table 1 shows that the efficacy of chq against malarial infection 
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Figure 1. Distribution of liposomes in various tissues. Values shown are mean of 4 
animals ± SD. (A) Normal mice. (B) P. berghei-infected mice. Tissue distributions were 
determined 15 min after injecting the liposomes, essentially as described earlier (Singhal 
and Gupta 1986). The non-targeted liposomes were radio-labelled by incorporating traces of 
egg [14C] PC in their bilayers, while the 'targeted liposomes besides having egg [14C] PC 
in their bilayers also contained [125I] labelled F(ab,)2 on their surface. (⁪), Non-targeted 
liposomal [14C] ; (■), targeted liposomal [14C ] ; ( ), targeted liposomal [125I]. 
 
Table 1. Efficacy of chq against chq-sensitive P. berghei infection in mice after 
encapsulation in targeted liposomes. 
 
Treatments were given on day 4 after the infection. Values are mean ± SE.
 
was considerably increased by delivering it in targeted liposomes; both the per cent 
survival and per cent parasitaemia suppression were high in the liposomized chq- 
treated animals as compared to those treated with free chq. This result is in 
agreement with earlier studies (Agrawal et al 1987). 
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To ascertain whether this method of chq delivery could be effective in controlling
the chq-resistant malarial infections also, we evaluated the efficacy of free and 
liposomized chq in mice which were infected with chq-resistant P. berghei. The 
parasites were made resistant to chq as described earlier in §2. The chq resistance 
was ascertained after treating the infected animals with chq. While this drug failed 
to eliminate the resistant infections even at 50mg/kg×4 days (i.p) dose, it 
completely cured the chq-sensitive infections at a much lower dose (15 mg/kg× 4 
days, i.p.). 
Table 2 shows that parasitaemias in chq-resistant P. berghei-infected mice after
treatment with free chq were similar to those observed in saline or drug-free 
liposome-treated animals. However, the same doses of chq were very effective in 
controlling the chq-resistant infections when delivered in targeted liposomes (table 
2). A 5 mg/kg dose of the liposomized chq appeared optimal, as the antimalarial 
effect did not significantly improve by increasing the drug dose (data not shown). 
This dose (5 mg/kg) of the liposomized chq was very effective in suppressing the 
parasitaemias at least up to day 12 after the infection (figure 2). Also, it considerably 
prolonged the survival time of the treated animals, when compared to the animals 
which were given chq in free form (figure 3),
 
 
4. Discussion 
 
This study demonstrates that efficacy of chq against the malarial infection is 
markedly increased by delivering this drug in anti-erythrocyte F(ab')2-bearing 
liposomes. The liposomized chq is effective in controlling not only the chq-sensitive 
infections but also the infections that were resistant to free chq. The latter effect of 
the liposomized chq appears to be related to the ability of our liposomes to 
concentrate the drug in erythrocyte, as chq encapsulated in nontargeted liposomes 
failed to exhibit any effect against the resistant infections (table 2).
Although the targeted liposomes used in this study were derived by covalently 
attaching anti-mouse erythrocyte F(ab')2 to the liposome surface, their ability to 
specifically recognize erythrocytes in vivo was not altered by the malarial infection 
(figure 1). This may be attributed to the wider specificity of our antibodies, the low 
degree of infection or both.
 
 
 
Table 2. Efficacy of chq against chq-resistant P. berghei infection in mice after 
encapsulation in targeted liposomes.
 
Treatments were given on day 4 after the infection. Values are mean ± SE
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Figure 2. Efficacy of chq-laden targeted liposomes against chq-resistant P. berghei infection on 
various days after the treatment. The treatments were given on day 4 after the infection. 
Parasitaemia suppression was calculated by using the parasitaemias in free chq-treated 
animals as the control values (A) chq at 2·5 mg/kg dose. (B) chq at 5 mg/kg dose. Values 
are means ± SE. The number of animals used in each group was ten.
 
 
 
 
 
Figure 3. Effect of chq treatment before (broken line) and after (solid line) encapsulating
the drug in targeted liposomes, on long-term survival of animals infected with chq-resistant 
P. berghei. The treatments (5 mg/kg dose of chq) were given on day 4 after the infection. 
Numbers in parentheses denote the number of animals surviving on a given day after the 
infection. 
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Peeters et al (1989) who recently studied the effect of liposomized chq on the chq-
resistant P. berghei infections showed that encapsulation of chq in liposomes (non- 
targeted) increased not only the maximal tolerable dose from 0·8 to 10 mg 
chq/animal when given intraperitoneally but also the drug effectivity against the 
infections. A dose of 8 mg chq/mouse/day for three consecutive days was found to 
be the most effective. Although we have given only a single intravenous dose 
(5 mg/kg) of chq in targeted liposomes, which was much smaller than that used by 
these workers (2–8 mg/mouse), the antiparasitic effect observed by us against the 
chq-resistant infections was still quite significant. This finding clearly suggests that 
chq delivery in targeted liposomes could be successful in curing the chq-resistant 
infections, using low drug doses. 
The demonstrated biologic response of chq-laden targeted liposomes against the 
chq-resistant malarial infections is not optimal, and may further be improved by 
using an infected erythrocyte-specific antibody rather than the nonspecific antibody, 
as used in this study. Also, the response may increase by changing the route of 
administration, and increasing the dose number. Finally, the intracellular 
concentration of chq in erythrocytes infected with chq-resistant P. berghei strain 
may be increased by encapsulating an appropriate Ca2+-channel inhibitor along 
with chq in targeted liposomes, which in turn should increase the antimalarial 
activity (Martin et al 1987). 
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